Trial Profile

A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naporafenib (Primary) ; Spartalizumab
Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

20 Dec 2022 Status changed from completed to discontinued.
10 Mar 2022 Status changed from active, no longer recruiting to completed.
09 Nov 2021 Planned End Date changed from 4 Nov 2021 to 25 Feb 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com